GATA1 recognizes GATA-containing cis-regulatory DNA and combines with different transcriptional partners to activate or repress RNA polymerase II genes. Human promoter studies supply direct DNA and transcription evidence, while lineage phenotypes explain why those regulatory mechanisms matter. The core synthesis joins that molecular activity to erythroid and megakaryocytic differentiation and eosinophil commitment. It does not turn every tissue association into a core developmental process (PMID:2467208(https://pubmed.ncbi.nlm.nih.gov/2467208/), PMID:22235304(https://pubmed.ncbi.nlm.nih.gov/22235304/), PMID:12045236(https://pubmed.ncbi.nlm.nih.gov/12045236/)).
The source studies distinguish DNA recognition from cofactor recruitment. V205M and D218G weaken FOG binding while preserving tested DNA interaction; R216Q has a different DNA-binding defect. FOG1 is a transcriptional coregulator, whereas MED1 and CCAR1 participate in coactivation. GATA1 complexes involving TAL1/LDB1, FOG1/MeCP1, GFI1B and chromatin-remodelling components are not collapsed into one supercomplex. These distinctions motivate specific binding replacements and preserve the positive experimental observations (PMID:10700180(https://pubmed.ncbi.nlm.nih.gov/10700180/), PMID:11418466(https://pubmed.ncbi.nlm.nih.gov/11418466/), PMID:12200364(https://pubmed.ncbi.nlm.nih.gov/12200364/), PMID:15920471(https://pubmed.ncbi.nlm.nih.gov/15920471/), PMID:24245781(https://pubmed.ncbi.nlm.nih.gov/24245781/)).
The three current natural sequences are distinct: full-length 413 residues, a 335-residue alternative splice product and 330-residue GATA1s. The original alternative-initiation study contains human endogenous observations but murine functional constructs. The available HI-II-14 target clone is sequence-identical to the 335-residue product; the interaction rows themselves do not assign clone identities per pair. Neither evidence permits assigning every function to every natural form (PMID:8524811(https://pubmed.ncbi.nlm.nih.gov/8524811/), PMID:16783379(https://pubmed.ncbi.nlm.nih.gov/16783379/), PMID:25416956(https://pubmed.ncbi.nlm.nih.gov/25416956/)).
Original supplementary target rows support the NRF2 and engineered SPOP-F133L interactions. The positive observations survive any removal of uninformative generic protein binding. Q8TES7-6 remains unresolved because the retained identity crosswalk does not map it; assigning an unmatched gene by elimination would manufacture evidence. Exact target subsets and assay limits are portable in GATA1 external target evidence (PMID:32911434(https://pubmed.ncbi.nlm.nih.gov/32911434/), PMID:35512704(https://pubmed.ncbi.nlm.nih.gov/35512704/)).
Caspase-3 is the literal partner of the source-specific cleavage row, and Hsp70 protection is a separate result. Epo-withdrawal observations differ from Hsp70-depletion rescue with Epo and IL3 present. The precise absent-ligand process remains unresolved, while the demonstrated survival and differentiation roles remain represented (PMID:17167422(https://pubmed.ncbi.nlm.nih.gov/17167422/)). Surface platelet-glycoprotein changes likewise do not distinguish synthesis from trafficking or turnover without the original assay; the source-specific biosynthesis contexts remain UNDECIDED (PMID:15701726(https://pubmed.ncbi.nlm.nih.gov/15701726/)).
The anatomical-morphogenesis context is kept as non-core after checking the actual platelet-formation → megakaryocyte-development → cell-morphogenesis ancestry. This closes a provisional over-annotation interpretation without changing the source record. Other broad anatomical/system or regenerative contexts retain their distinct evidence limits. Rat testicular and mast-cell donor experiments are recorded as donor evidence, not direct human assays; the original cryptorchidism report explicitly leaves the causal relation uncertain.
All 120 current contexts were manually assessed: 57 ACCEPT, 33 MODIFY, 11 KEEP_AS_NON_CORE, 8 REMOVE, 8 UNDECIDED and 3 MARK_AS_OVER_ANNOTATED. No NEW annotation is proposed. The source archive preserves every supplied field, all six conjunctive extension contexts/eight atoms and the genuine phylogenetic origins. There is no inherited target review or journal at the qualified base. Native acquisition, actual seed reconciliation and validation have not occurred; the proposal retains explicit nulls for those future results.
The initial private-stage paragraph above is retained as the dated preparation record. The genuine native fetch has now produced 120 annotations and three product records. All 120 original contexts and all 16 export columns reconcile; six conjunctive extension contexts/eight atoms are restored explicitly. The 58 available source files comprise 28 unchanged main sources, three immutable GATA2 publications and 27 newly acquired missing-only sources. R-HSA-983231 remains unavailable with the prior N-owned HTTP521 diagnostic; no placeholder or duplicate fetch was made. Seven short excerpts match actual cache or portable-file bytes.
The accepted native policy adaptation changes only original raw61/GO:0009653 from KEEP_AS_NON_CORE to TOO_GENERAL: platelet formation GO:0030220 already entails anatomical structure morphogenesis through verified is_a/part_of ancestry. The assertion remains true; its broad wording adds no specificity. Other ten non-core contexts are unchanged. Current actions are 57 ACCEPT, 33 MODIFY, 10 KEEP_AS_NON_CORE, 1 TOO_GENERAL, 8 REMOVE, 8 UNDECIDED and 3 MARK_AS_OVER_ANNOTATED. The original 120 manual decisions remain preserved in the private frozen packet. Native title/access metadata and the product3 native name are recorded as normalization; the biological product scopes and source judgments are unchanged. Native codex CREATE history records these adaptations. Default validation passed with one intentional action-consistency advisory: GO:0061629 is accepted for the PU.1 DNA-binding transcription-factor partner but refined to transcription coregulator binding for the distinct FOG1 partner. Strict GOA matched all 120 originals, native history passed, and the status audit computes DRAFT while eight source-specific judgments remain UNDECIDED. Private rendering, links and scoped whitespace checks passed.
The retained original PMID:28473536 workbook was subsequently recovered through the shared evidence archive. Its GATA1 S1 row 293 and S2 rows 8218/8223 identify the eDBD constructs underlying the two positive DNA-binding models. This closes the earlier target-table access limit without changing the MOD action, its independent promoter-based specificity, natural-product claims or the seven existing quotations.
The initial published record and earlier journal entries above are preserved. Direct identity reading of the retained UniProt Q8TES7 record resolves FBF1/GeneID 85302 and its declared isoform 6; the earlier unresolved-gene interpretation was too narrow. Table S2G row 1874 retains the positive GATA1–FBF1 pair. Its generic binding action changes from UNDECIDED to REMOVE for informativeness; exact pair-specific clone equivalence remains unproven (PMID:25416956(https://pubmed.ncbi.nlm.nih.gov/25416956/); portable identity and table locators).
The broad morphogenesis reason now uses the correct label platelet morphogenesis for GO:0036344. The official path is GO:0030220 part_of GO:0036344 is_a GO:0000902 is_a GO:0009653. This corrects the earlier prose without changing TOO_GENERAL or the original electronic fields. Cell-fate commitment remains core across lineages. The CASP3 extension keeps its exact BFO:0000050/GO:0043065 relationship and gains the descriptive label positive regulation of apoptotic process.
Source-specific response distinctions are explicit in the source guide: LPS has promoter-binding/output context and remains non-core, while the newly read original testicular study does not establish a GATA1-mediated cAMP/FSH response step. The two latter actions become MARK_AS_OVER_ANNOTATED; positive expression and reported EMSA observations remain intact. Sertoli-development U is based on a different paper. HOXA1 and HEXIM2 retain specific binding refinements after original HI-II-14 retesting criteria were checked; no physiological program or pair-specific orthogonal validation is inferred.
GATA1s biology is added to the standalone summary and existing product descriptions: loss of the N-terminal transactivation region, context-qualified functional comparison, human short-form-only erythropoietic impairment, and Down-syndrome-associated transient abnormal myelopoiesis/acute megakaryoblastic leukemia context (PMID:8524811(https://pubmed.ncbi.nlm.nih.gov/8524811/), PMID:16783379(https://pubmed.ncbi.nlm.nih.gov/16783379/)). Natural alternative initiation is distinguished from disease-associated mutations and the 335-residue splice product. No unsupported schema enum or new annotation is introduced.
The proposed totals are 57 ACCEPT, 33 MODIFY, 8 KEEP_AS_NON_CORE, 1 TOO_GENERAL, 9 REMOVE, 7 UNDECIDED and 5 MARK_AS_OVER_ANNOTATED. All 120 original assertions, three product identities/sequences, eight extension atoms, one core, 54 references and seven exact excerpts are conserved. Only the portable-file quotation offsets/hash move with its added explanation. All 58 normal source bytes remain unchanged. Affected checks passed: default validation with the intentional GO:0061629 partner-specific advisory, strict GOA matching all 120 originals, genuine codex EDIT history, computed DRAFT status with seven UNDECIDED judgments, private rendering and local links, and scoped whitespace. No normal source or ontology-cache bytes changed. The prior published results remain distinct from these amendment checks.